Key result
Direct reversal strategies appear more effective than nonspecific hemostatic agents for DOAC-induced bleeding.
Why the study?
To provide evidence-based management of patients on direct oral anticoagulants needing acute procedures, including those facing hemorrhage.
What are the optimal diagnostic and management strategies for DOAC-induced bleeding or in DOAC-treated patients needing acute procedures?
What are the optimal diagnostic and management strategies for DOAC-induced bleeding or in DOAC-treated patients needing acute procedures?
Clinicians must carefully assess bleeding risk and hemorrhage severity in DOAC-treated patients before initiating reversal treatments, utilizing specific assays and direct reversal agents when appropriate.
Answers are grounded in this paper and cite their sources.
May support preferring direct reversal after risk assessment in DOAC bleeding; leaves open RCTs to confirm superiority over nonspecific agents.
PURPOSE OF REVIEW: To provide evidence-based management of patients on direct oral anticoagulants (DOAC) needing acute procedures, including those facing hemorrhage. RECENT FINDINGS: Standard coagulation parameters are insufficient for precise DOAC plasma level measurement; calibrated anti factor X activated assays are reliable, and point-of-care assays may be useful in urgent situations. For intracerebral hemorrhage (ICH) in patients on DOACs, direct reversal strategies seem to be more effective than nonspecific hemostatic agents, but evidence still remains unclear in terms of efficacy and safety compared to nonspecific hemostatic agents. Before invasive procedures like neuraxial anesthesia or cerebral thrombectomy, idarucizumab is recommended for dabigatran-treated patients, despite recent observational data not fully supporting this. No recommendations can be made for FXa inhibitors because of the lack of data. SUMMARY: Clinicians should assess the overall risk of bleeding for an acute procedure or the severity of any ongoing hemorrhage in DOAC-treated patients before initiating any reversal treatment, regardless of current evidence levels.
No takes yet. Share an insight, caveat, or question.
Heymann et al. (2025) conducted a review in DOAC-induced bleeding and acute procedures in DOAC-treated patients. Direct reversal strategies (e.g., idarucizumab) vs. Nonspecific hemostatic agents was evaluated. Direct reversal strategies for DOAC-induced bleeding appear more effective than nonspecific hemostatic agents, though clinicians must assess overall bleeding risk before initiating treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: